Developer docs
API playgroundTry for free, no card

Search company profiles

Vyrsa Technologies

Full company profile

uuid000jqw3

Namestring
Vyrsa Technologies
Legal namestring
VYRSA Technologies
Websiteurl
vyrsatech.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Vyrsa Technologies is a medical device company specializing in sacroiliac (SI) joint fusion technologies, founded in 2021 and headquartered in King of Prussia, Pennsylvania. The company developed an FDA 510k-cleared implant portfolio anchored by the Nevro1™ (originally branded V1) implant, which uses proprietary integrated lateral transfixation technology with self-deploying titanium anchors to provide axial and rotational stability of the SI joint through a minimally invasive posterior approach. The portfolio was expanded to include NevroPro™ (a custom cortical allograft implant using a novel inferior inlet approach) and NevroFix™ (lateral fixation screws), enabling a comprehensive hybrid surgical technique that combines articular decortication, fixation, and compression. The underlying technology is backed by a 2+ year biomechanics study involving 24 cadaveric trials, 30 motion measurements, and 100k cyclical loads, conducted in collaboration with the FDA. Clinical evidence cites 73% mean pain reduction and 83% clinically significant improvement across a systematic review of 17 studies covering 1,227 patients.

Vyrsa generated revenue through hardware sales of FDA-cleared implants and surgical systems to healthcare providers under a sales-led go-to-market model targeting orthopedic surgeons, neurosurgeons, and pain management specialists performing SI joint fusion procedures. Distribution ran through medical device sales channels including direct hospital sales and physician-directed device ordering, supplemented by medical conferences, physician education programs, peer-reviewed clinical publications, and professional referral networks. The company held a worldwide exclusive license from Camber Spine for the foundational transfixation IP and operated with 11-50 employees. In November 2023, Vyrsa was acquired by Nevro Corp, a publicly traded medical technology company focused on chronic pain, integrating Vyrsa's SI joint fusion portfolio alongside Nevro's HFX 10 kHz Therapy platform.

Short descriptiontext

Vyrsa Technologies is a medical device company that develops FDA-cleared sacroiliac joint fusion implants — including the Nevro1™, NevroPro™, and NevroFix™ systems — for orthopedic surgeons, neurosurgeons, and pain management specialists treating chronic SI joint pain. Acquired by Nevro Corp in November 2023.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersKing Of Prussia, United States
HQ citystring
King Of Prussia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sacroiliac joint fusion, minimally invasive spine surgery, orthopedic medical devices, SI joint implants, chronic pain treatment
Industry3 codes
PRIMARYHLAHAEAC
Spine Implants & Motion Preservation (Fusion/Disc/Interspinous)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Spine Surgical Implants
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Vyrsa Technologies generates revenue through the sale of FDA-cleared sacroiliac joint fusion implants and surgical systems to healthcare providers and hospitals. The company operates as a medical device manufacturer serving the spine surgery market.

openpr.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Nevro1™
Description

FDA 510k-cleared sacroiliac joint fusion implant featuring integrated lateral transfixation technology, formerly known as V1 implant

vyrsatech.com
+2 more records
Core offering1 text field

Vyrsa Technologies develops and sells FDA 510k-cleared medical devices for minimally invasive sacroiliac (SI) joint fusion surgery. The core product portfolio includes the Nevro1™ titanium implant with integrated lateral transfixation technology, the NevroPro™ cortical allograft implant using a novel inferior inlet approach, and NevroFix™ lateral fixation screws. These implants are sold to orthopedic surgeons, neurosurgeons, and pain management specialists for the treatment of chronic SI joint pain and degenerative sacroiliitis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 73% mean pain reduction post-fusion
+2 more records
Product overview1 text field

Vyrsa Technologies offers a portfolio of FDA-cleared medical devices for sacroiliac (SI) joint fusion surgery. The core product lineup includes Nevro1™ (a titanium implant with lateral transfixation technology), NevroPro™ (a custom cortical allograft implant using an inferior inlet approach), and NevroFix™ (lateral fixation screws). The company was acquired by Nevro Corp in November 2023 and operates as part of Nevro's portfolio of chronic pain treatment solutions.

Product and service3 records
1Nevro1™ SI Joint Fusion System
CategorySacroiliac joint fusion implant
Description

FDA 510k-cleared sacroiliac joint fusion implant featuring integrated lateral transfixation technology with self-contained, deployable titanium anchors that transfix the sacrum and ilium for immediate axial and rotational stability, sold to orthopedic surgeons, neurosurgeons, and pain management specialists for minimally invasive SI joint fusion.

2NevroPro™ SI Fusion System
CategorySacroiliac joint fusion implant
Description

First MIS posterior allograft SI fusion system designed for comprehensive decortication of the SIJ articular surface using a novel inferior inlet approach; custom bone allograft implant offered in multiple sizes for variable patient anatomy, sold to spine surgeons.

3NevroFix™ Lateral Fixation Screws
CategorySacroiliac joint fixation screws
Description

Lateral sacroiliac joint fixation screws designed to provide superior compression in comparison to other threaded fixation implants, sold as part of the SI joint fusion portfolio to spine surgeons.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-01
Description

In November 2023, Nevro Corp acquired Vyrsa Technologies to strengthen its minimally invasive treatment offerings for sacroiliac joint fusion. The acquisition brought VYRSA's FDA-cleared V1 implant technology under Nevro's portfolio.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Comprehensive 2+ year biomechanics analysis performed in collaboration with the FDA to establish effective stabilization of the SI joint. This collaboration led to FDA 510k clearance in Q4 2022.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

VYRSA Technologies acquired worldwide exclusive license for patented sacroiliac joint fusion technology with integrated lateral transfixation from Camber Spine under the name VYRSA V1.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Biomechanics testing facility located at Allegheny Singer Research Institute, Department of Neuroscience. Principal Investigator: Boyle Cheng, PhD, Professor of Neurosurgery at Drexel University College of Medicine and Director of Neurosurgical & Spine Research at Allegheny General Hospital.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers9 records
TypeBroad incumbent
Description

Stryker's spine and orthopedic trauma divisions offer a broad range of fusion implants, fixation, and biologics used in spine and pelvic surgery. As a diversified medtech incumbent, it overlaps with Vyrsa's hospital customer base and procedural categories.

TypeBroad incumbent
Description

Medtronic is the largest spine hardware incumbent with broad fusion, fixation, and biologics portfolios. Its spine division targets the same orthopedic and neurosurgery call points as Vyrsa, making it a broad incumbent peer despite not specializing in SI joint fusion.

TypeBroad incumbent
Description

Orthofix offers spine hardware, biologics, and orthopedic solutions targeting the same hospital/surgeon channels as Vyrsa/Nevro. It is a broad incumbent in spine fusion and motion preservation procedures relevant to the SI joint patient population.

TypeDirect peer
Description

SI-Bone pioneered the MIS sacroiliac joint fusion market with its iFuse Implant System and remains the dominant category-defining competitor to Vyrsa/Nevro1. Both companies target the same spine/pain physician call point with transiliac/triangular titanium implants for SI joint fusion.

TypeBroad incumbent
Description

Globus Medical (now including NuVasive) is one of the largest spine hardware companies with a broad portfolio including SI joint fusion offerings. It competes indirectly with Vyrsa/Nevro through comprehensive spine surgery solutions sold to the same surgeon base.

TypeEmerging player
Description

PainTEQ markets the LinQ minimally invasive SI joint fusion system, directly competing with Nevro1 in the same procedure category with a similar posterior allograft approach to Vyrsa's NevroPro. It is an emerging focused competitor in MIS SI joint stabilization.

TypeEmerging player
Description

Alphatec is a growth-oriented spine company focused on procedural innovation in fusion and lateral approaches. It is comparable as an emerging focused spine hardware player competing for the same surgeon mindshare in adjacent procedural categories to Vyrsa's SI joint portfolio.

TypeBroad incumbent
Description

Boston Scientific operates a meaningful spine pain franchise (via Vertiflex and other acquisitions) targeting overlapping pain-management and spine call points. It serves as a broad incumbent peer across the chronic pain patient pathway Vyrsa addresses.

TypeDirect peer
Description

Camber Spine is the original developer of the integrated lateral transfixation technology that Vyrsa exclusively licensed for the Nevro1/V1 implant, and continues to develop SI joint and other spine technologies. It is directly comparable as the originating IP holder and an active SI joint fusion peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vyrsa Technologies

Spine Surgical Implantsvyrsatech.com

Vyrsa Technologies is a medical device company that develops FDA-cleared sacroiliac joint fusion implants — including the Nevro1™, NevroPro™, and NevroFix™ systems — for orthopedic surgeons, neurosurgeons, and pain management specialists treating chronic SI joint pain. Acquired by Nevro Corp in November 2023.

What Vyrsa Technologies does

Vyrsa Technologies is a medical device company specializing in sacroiliac (SI) joint fusion technologies, founded in 2021 and headquartered in King of Prussia, Pennsylvania. The company developed an FDA 510k-cleared implant portfolio anchored by the Nevro1™ (originally branded V1) implant, which uses proprietary integrated lateral transfixation technology with self-deploying titanium anchors to provide axial and rotational stability of the SI joint through a minimally invasive posterior approach. The portfolio was expanded to include NevroPro™ (a custom cortical allograft implant using a novel inferior inlet approach) and NevroFix™ (lateral fixation screws), enabling a comprehensive hybrid surgical technique that combines articular decortication, fixation, and compression. The underlying technology is backed by a 2+ year biomechanics study involving 24 cadaveric trials, 30 motion measurements, and 100k cyclical loads, conducted in collaboration with the FDA. Clinical evidence cites 73% mean pain reduction and 83% clinically significant improvement across a systematic review of 17 studies covering 1,227 patients.

Vyrsa generated revenue through hardware sales of FDA-cleared implants and surgical systems to healthcare providers under a sales-led go-to-market model targeting orthopedic surgeons, neurosurgeons, and pain management specialists performing SI joint fusion procedures. Distribution ran through medical device sales channels including direct hospital sales and physician-directed device ordering, supplemented by medical conferences, physician education programs, peer-reviewed clinical publications, and professional referral networks. The company held a worldwide exclusive license from Camber Spine for the foundational transfixation IP and operated with 11-50 employees. In November 2023, Vyrsa was acquired by Nevro Corp, a publicly traded medical technology company focused on chronic pain, integrating Vyrsa's SI joint fusion portfolio alongside Nevro's HFX 10 kHz Therapy platform.

Vyrsa Technologies firmographics

Firmographics
Name
Vyrsa Technologies
Legal name
VYRSA Technologies
Website
https://vyrsatech.com
Company type
Private
Founded year
2021
Operating status
Acquired
Headcount range
1–10 employees
Short description
Vyrsa Technologies is a medical device company that develops FDA-cleared sacroiliac joint fusion implants — including the Nevro1™, NevroPro™, and NevroFix™ systems — for orthopedic surgeons, neurosurgeons, and pain management specialists treating chronic SI joint pain. Acquired by Nevro Corp in November 2023.
Ownership category
akta.pro rank

Vyrsa Technologies industry classification

Industry
Product category
Spine Surgical Implants
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAEAC
Spine Implants & Motion Preservation (Fusion/Disc/Interspinous)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Sacroiliac joint fusion
  • Minimally invasive spine surgery
  • Orthopedic medical devices
  • SI joint implants
  • Chronic pain treatment

Where Vyrsa Technologies is headquartered

Location

Headquarters

HQ city
King Of Prussia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Vyrsa Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Medical Device Sales: Vyrsa Technologies generates revenue through the sale of FDA-cleared sacroiliac joint fusion implants and surgical systems to healthcare providers and hospitals. The company operates as a medical device manufacturer serving the spine surgery market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Vyrsa Technologies product offering

Product offering

Core offering

Vyrsa Technologies develops and sells FDA 510k-cleared medical devices for minimally invasive sacroiliac (SI) joint fusion surgery. The core product portfolio includes the Nevro1™ titanium implant with integrated lateral transfixation technology, the NevroPro™ cortical allograft implant using a novel inferior inlet approach, and NevroFix™ lateral fixation screws. These implants are sold to orthopedic surgeons, neurosurgeons, and pain management specialists for the treatment of chronic SI joint pain and degenerative sacroiliitis.

Product overview

Vyrsa Technologies offers a portfolio of FDA-cleared medical devices for sacroiliac (SI) joint fusion surgery. The core product lineup includes Nevro1™ (a titanium implant with lateral transfixation technology), NevroPro™ (a custom cortical allograft implant using an inferior inlet approach), and NevroFix™ (lateral fixation screws). The company was acquired by Nevro Corp in November 2023 and operates as part of Nevro's portfolio of chronic pain treatment solutions.

Differentiator

Problem solved

Functional benefit

Brands

  • Nevro1™: FDA 510k-cleared sacroiliac joint fusion implant featuring integrated lateral transfixation technology, formerly known as V1 implant
  • NevroPro™
  • NevroFix™

Products and services

  • Nevro1™ SI Joint Fusion System FDA 510k-cleared sacroiliac joint fusion implant featuring integrated lateral transfixation technology with self-contained, deployable titanium anchors that transfix the sacrum and ilium for immediate axial and rotational stability, sold to orthopedic surgeons, neurosurgeons, and pain management specialists for minimally invasive SI joint fusion.
  • NevroPro™ SI Fusion System First MIS posterior allograft SI fusion system designed for comprehensive decortication of the SIJ articular surface using a novel inferior inlet approach; custom bone allograft implant offered in multiple sizes for variable patient anatomy, sold to spine surgeons.
  • NevroFix™ Lateral Fixation Screws Lateral sacroiliac joint fixation screws designed to provide superior compression in comparison to other threaded fixation implants, sold as part of the SI joint fusion portfolio to spine surgeons.

Quantifiable outcome

  • 73% mean pain reduction post-fusion
  • +2 more outcomes

Companies that use Vyrsa Technologies

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Vyrsa Technologies technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Vyrsa Technologies partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and major.

  • Nevro CorpcoreStrategic or Co-development Partner · 1 November 2023In November 2023, Nevro Corp acquired Vyrsa Technologies to strengthen its minimally invasive treatment offerings for sacroiliac joint fusion. The acquisition brought VYRSA's FDA-cleared V1 implant technology under Nevro's portfolio.
  • FDAcoreStrategic or Co-development PartnerComprehensive 2+ year biomechanics analysis performed in collaboration with the FDA to establish effective stabilization of the SI joint. This collaboration led to FDA 510k clearance in Q4 2022.
  • Camber SpinecoreOEM/ Whitelabel/ Licensing PartnerVYRSA Technologies acquired worldwide exclusive license for patented sacroiliac joint fusion technology with integrated lateral transfixation from Camber Spine under the name VYRSA V1.
  • Allegheny Health Network - Spine Research LabmajorStrategic or Co-development PartnerBiomechanics testing facility located at Allegheny Singer Research Institute, Department of Neuroscience. Principal Investigator: Boyle Cheng, PhD, Professor of Neurosurgery at Drexel University College of Medicine and Director of Neurosurgical & Spine Research at Allegheny General Hospital.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Vyrsa Technologies competitors and assessment

Company assessment

Broad incumbents

  • Stryker: Stryker's spine and orthopedic trauma divisions offer a broad range of fusion implants, fixation, and biologics used in spine and pelvic surgery. As a diversified medtech incumbent, it overlaps with Vyrsa's hospital customer base and procedural categories.
  • Medtronic: Medtronic is the largest spine hardware incumbent with broad fusion, fixation, and biologics portfolios. Its spine division targets the same orthopedic and neurosurgery call points as Vyrsa, making it a broad incumbent peer despite not specializing in SI joint fusion.
  • Orthofix Medical: Orthofix offers spine hardware, biologics, and orthopedic solutions targeting the same hospital/surgeon channels as Vyrsa/Nevro. It is a broad incumbent in spine fusion and motion preservation procedures relevant to the SI joint patient population.
  • Globus Medical: Globus Medical (now including NuVasive) is one of the largest spine hardware companies with a broad portfolio including SI joint fusion offerings. It competes indirectly with Vyrsa/Nevro through comprehensive spine surgery solutions sold to the same surgeon base.
  • Boston Scientific: Boston Scientific operates a meaningful spine pain franchise (via Vertiflex and other acquisitions) targeting overlapping pain-management and spine call points. It serves as a broad incumbent peer across the chronic pain patient pathway Vyrsa addresses.

Direct peers

  • SI-Bone: SI-Bone pioneered the MIS sacroiliac joint fusion market with its iFuse Implant System and remains the dominant category-defining competitor to Vyrsa/Nevro1. Both companies target the same spine/pain physician call point with transiliac/triangular titanium implants for SI joint fusion.
  • Camber Spine: Camber Spine is the original developer of the integrated lateral transfixation technology that Vyrsa exclusively licensed for the Nevro1/V1 implant, and continues to develop SI joint and other spine technologies. It is directly comparable as the originating IP holder and an active SI joint fusion peer.

Emerging players

  • PainTEQ: PainTEQ markets the LinQ minimally invasive SI joint fusion system, directly competing with Nevro1 in the same procedure category with a similar posterior allograft approach to Vyrsa's NevroPro. It is an emerging focused competitor in MIS SI joint stabilization.
  • Alphatec Holdings: Alphatec is a growth-oriented spine company focused on procedural innovation in fusion and lateral approaches. It is comparable as an emerging focused spine hardware player competing for the same surgeon mindshare in adjacent procedural categories to Vyrsa's SI joint portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Vyrsa Technologies social profiles

Digital presence

Vyrsa Technologies compliance and trust

Trust signal

Compliance1 record

Vyrsa Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vyrsa Technologies leadership team

Management profile

Number of profiles

Vyrsa Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vyrsa Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vyrsa Technologies

What does Vyrsa Technologies do?

Vyrsa Technologies develops and sells FDA 510k-cleared medical devices for minimally invasive sacroiliac (SI) joint fusion surgery. The core product portfolio includes the Nevro1™ titanium implant with integrated lateral transfixation technology, the NevroPro™ cortical allograft implant using a novel inferior inlet approach, and NevroFix™ lateral fixation screws. These implants are sold to orthopedic surgeons, neurosurgeons, and pain management specialists for the treatment of chronic SI joint pain and degenerative sacroiliitis.

Is Vyrsa Technologies a public or private company?

Vyrsa Technologies is a private company. It is classified as corporate owned and is currently acquired.

When was Vyrsa Technologies founded?

Vyrsa Technologies was founded in 2021. It employs 1 to 10 people.

Where is Vyrsa Technologies based?

Vyrsa Technologies is headquartered in King Of Prussia, United States, in the North America region.

How does Vyrsa Technologies make money?

One revenue line is on record: medical Device Sales.

Who are Vyrsa Technologies's main competitors?

Broad incumbents on record are Stryker, Medtronic, Orthofix Medical, Globus Medical and Boston Scientific. Direct peers are SI-Bone and Camber Spine. Emerging players are PainTEQ and Alphatec Holdings.

Does Vyrsa Technologies have an API?

No public API is recorded for Vyrsa Technologies.

What industry is Vyrsa Technologies in?

Vyrsa Technologies's product category is Spine Surgical Implants. Its primary akta.pro industry code is HLAHAEAC, Spine Implants & Motion Preservation (Fusion/Disc/Interspinous), with a secondary code of HLAHAEAB, Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comLeading Companies Enhancing Their Presence in the Sacroiliitis Treatment MarketThe sacroiliitis treatment market is projected to grow to $2.5 billion by 2030, representing a compound annual growth rate of 7.1%, driven by increased use of biologic medications, minimally invasive procedures, and digital diagnostic technologies. In November 2023, Nevro Corp. acquired Vyrsa Technologies to strengthen its minimally invasive treatment offerings for sacroiliac joint fusion. In December 2023, Spinal Simplicity received FDA 510(k) clearance for its Liberty-SI Lateral Implant System, a minimally invasive device for sacroiliac joint fusion.PR NewswireNevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral ScrewNevro Corp. received FDA 510(k) clearance for its Nevro1 sacroiliac joint fusion device to be marketed without the mandatory inclusion of the lateral screw component. This regulatory approval marks the first clearance since Nevro acquired Vyrsa Technologies in November 2023, with the rights transferred from Camber Spine. The company describes the standalone device as a significant advancement offering enhanced stability and bone growth promotion for SI joint fusion.PR NewswireNevro Reports Fourth-Quarter and Full-Year 2023 Financial ResultsNevro Corp. reported fourth-quarter and full-year 2023 financial results, highlighting a 2% revenue increase to $116.2 million in Q4 and the acquisition of Vyrsa Technologies to expand its chronic pain treatment portfolio. The company also announced a restructuring involving a 5% workforce reduction and provided 2024 guidance projecting full-year revenue growth of 2% to 5% despite expected adjusted EBITDA losses.G-MedtechNevro Acquires Vyrsa Technologies for up to $75 MillionNevro Corp. has acquired Vyrsa Technologies, a medical technology firm specializing in minimally invasive treatments for sacroiliac joint pain, for an initial $40 million with up to $35 million in potential milestone payments. The acquisition integrates Vyrsa's FDA-cleared device portfolio into Nevro's offerings to target the growing US SI joint fusion market valued at over $2 billion.Medical BuyerNevro announces acquisition of Vyrsa™ TechnologiesNevro Corp. has completed the acquisition of Vyrsa Technologies for a base price of $40 million with potential additional milestone payments up to $35 million, expanding its portfolio in sacroiliac joint fusion devices. Concurrently, Nevro closed a $200 million term loan facility with Braidwell to refinance convertible notes and support working capital, aiming to limit equity dilution.PR NewswireNevro Announces Acquisition of Vyrsa™ TechnologiesNevro Corp. announced the acquisition of Vyrsa Technologies for a base price of $40 million plus up to $35 million in milestone payments, expanding its portfolio into the sacroiliac joint fusion market. Simultaneously, Nevro closed a $200 million term loan credit facility with Braidwell to refinance existing debt and support working capital.PR NewswireVYRSA Technologies Announces Worldwide Launch of the VYRSA V1™ SI Fusion SystemThe FDA granted 510(k) clearance to VYRSA Technologies for the VYRSA V1™ SI Fusion System, a 3D-printed titanium implant designed for sacroiliac joint fusion to treat pain from joint disruptions and degenerative sacroiliitis. The device underwent extensive 2.5-year biomechanical testing demonstrating biomechanical stability comparable to control implants. The company, based in King of Prussia, PA, views this clearance as a significant step toward entering the U.S. market for surgical treatment of musculoskeletal disorders.BioSpaceVYRSA Technologies, Inc. Appoints Earl R. Fender to the Corporate Board of DirectorsVYRSA Technologies appointed Earl R. Fender to its board of directors, effective November 1, 2022. Fender previously led Nalu and Vertiflex, and Boston Scientific acquired Vertiflex for $465M plus milestones. The company plans to launch its V1 Fusion System in 2023.PR NewswireVYRSA Technologies, Inc. Appoints Earl R. Fender to the Corporate Board of DirectorsVYRSA Technologies, Inc., a specialty medical device company based in King of Prussia, PA, announced the appointment of Earl R. Fender to its Board of Directors, effective November 1, 2022. Fender previously led Vertiflex, Inc. as President & CEO from 2008 to 2020, overseeing its acquisition by Boston Scientific in 2019 for $465 million plus milestones, and more recently served as President & CEO of Nalu from 2020 to 2022. The company plans to launch its FDA-cleared VYRSA V1 Fusion System, a transformational MIS SI fusion device, in 2023.